{
    "root": "11095ca8-ef1a-4f4e-a044-ac6d2186ee1a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IMPAVIDO",
    "value": "20250319",
    "ingredients": [
        {
            "name": "MILTEFOSINE",
            "code": "53EY29W7EC"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "impavido ( miltefosine ) capsules indicated adults pediatric patients 12 years age older weighing greater equal 30 kg ( 66 lbs ) treatment : \u2022visceral leishmaniasis caused leishmania donovani [ trials ( 14.1 ) ] . \u2022cutaneous leishmaniasis caused leishmania braziliensis , leishmania guyanensis , leishmania panamensis [ trials ( 14.2 ) ] . \u2022mucosal leishmaniasis caused leishmania braziliensis [ trials ( 14.3 ) ] . limitations : \u2022 leishmania species studied trials evaluating impavido based epidemiologic data [ trials ( 14.1 , 14.2 ) ] . \u2022there may geographic variation response leishmania species impavido [ trials ( 14.1 , 14.2 ) ] . \u2022the efficacy impavido treatment leishmania species evaluated .",
    "contraindications": "verify pregnancy status prior initiating impavido females reproductive potential [ , ( 8.3 ) ] . treatment duration 28 consecutive days . administer food ameliorate gastrointestinal . table 1 : impavido weight 30 kg 44 kg one 50 mg capsule twice daily food ( breakfast dinner ) 45 kg greater one 50 mg capsule three times daily food ( breakfast , lunch , dinner )",
    "warningsAndPrecautions": "impavido capsule contains 50 mg miltefosine opaque , red , hard gelatin capsule . impavido capsules supplied folded peel/push-through child-resistant blister card . blister card contains 14 capsules . carton contains two blister cards ( ndc 69051-300-01 ) . store 20-25 \u00b0c ( 68-77 \u00b0f ) ; excursions permitted 15-30 \u00b0c ( 59-86 \u00b0f ) . [ usp controlled room temperature ] . protect moisture . dispense original carton .",
    "adverseReactions": "\u2022 pregnancy ( 4.1 , 5.1 , 8.1 ) . \u2022 sj\u00f6gren-larsson-syndrome ( 4.2 , 12.3 ) . \u2022 hypersensitivity miltefosine excipients ( 4.3 ) .",
    "indications_original": "IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of:\n                  \n                     \n                        \u2022Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials (14.1)]. \n                     \n                        \u2022Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials (14.2)]. \n                     \n                        \u2022Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials (14.3)].\n                  \n                  \n                     Limitations of Use:\n                     \n                  \n                  \n                     \n                        \u2022\n                        Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials (14.1, 14.2)]. \n                     \n                        \u2022There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials (14.1, 14.2)]. \n                     \n                        \u2022The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.",
    "contraindications_original": "Verify pregnancy status prior to initiating IMPAVIDO in females of reproductive potential [see Use in Specific Populations, (8.3)].\n                  \n                  The treatment duration is 28 consecutive days. Administer with food to ameliorate gastrointestinal adverse reactions.\n                  \n                     Table 1: IMPAVIDO Dosage\n                     \n                     \n                     \n                        \n                           \n                              Weight\n                           \n                           \n                              Dosage and Administration\n                           \n                        \n                        \n                           \n                              30 kg to 44 kg\n                           \n                           \n                              One 50 mg capsule twice daily with food (breakfast and dinner) \n                           \n                        \n                        \n                           \n                              45 kg or greater \n                           \n                           \n                              One 50 mg capsule three times daily with food (breakfast, lunch, and dinner)",
    "warningsAndPrecautions_original": "Each IMPAVIDO capsule contains 50 mg miltefosine in an opaque, red, hard gelatin capsule. IMPAVIDO capsules are supplied in a folded peel/push-through child-resistant blister card.  Each blister card contains 14 capsules. Each carton contains two blister cards (NDC 69051-300-01).\n                  Store at 20-25 \u00b0C (68-77 \u00b0F); excursions permitted to 15-30 \u00b0C (59-86 \u00b0F). [See USP Controlled Room Temperature].  Protect from moisture. \n                  Dispense only in the original carton.",
    "adverseReactions_original": "\u2022 Pregnancy ( 4.1 , 5.1 , 8.1 ). \u2022 Sj\u00f6gren-Larsson-Syndrome ( 4.2 , 12.3 ). \u2022 Hypersensitivity to miltefosine or any of its excipients ( 4.3 )."
}